Therapeutic potential of the epidermal growth factor receptor transactivation in hypertension: A convergent signaling pathway of vascular tone, oxidative stress, and hypertrophic growth downstream of vasoactive G-protein-coupled receptors?

Canadian Journal of Physiology and Pharmacology

Volumn 85, Issue 1, 2007, Pages 97-104

  Fernandez Patron, Carlos ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

EGFR; Hypertension; MMP

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; G PROTEIN COUPLED RECEPTOR; MATRIX METALLOPROTEINASE; ADAM PROTEIN; ALPHA 1 ADRENERGIC RECEPTOR; ANTIHYPERTENSIVE AGENT; METALLOPROTEINASE; REACTIVE OXYGEN METABOLITE; VASOCONSTRICTOR AGENT;

BLOOD VESSEL TONE; HYPERTENSION; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; REVIEW; ANIMAL; BLOOD PRESSURE; CARDIOMEGALY; DRUG ANTAGONISM; DRUG EFFECT; HUMAN; METABOLISM; MITOCHONDRION; PATHOPHYSIOLOGY; SIGNAL TRANSDUCTION; VASOCONSTRICTION;

ADAM PROTEINS; ANIMALS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CARDIOMEGALY; HUMANS; HYPERTENSION; METALLOPROTEASES; MITOCHONDRIA; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, ADRENERGIC, ALPHA-1; RECEPTORS, G-PROTEIN-COUPLED; SIGNAL TRANSDUCTION; VASOCONSTRICTION; VASOCONSTRICTOR AGENTS;

EID: 34250858414     PISSN: 00084212     EISSN: None     Source Type: Journal    
DOI: 10.1139/Y06-097     Document Type: Review

References (59)

1. 2-sensitive potassium channels in the pulmonary circulation. Adv. Exp. Med. Biol. 475: 219-240.
2. Asakura, M., Kitakaze, M., Takashima, S., Liao, Y., Ishikura, F., Yoshinaka, T., et al. 2002. Cardiac hypertrophy is inhibited by antagonism of ADAM12 processing of HB-EGF: metalloproteinase inhibitors as a new therapy. Nat. Med. 8: 35-40. doi:10. 1038/nm0102-35.
3. Bendeck, M.P., Conte, M., Zhang, M., Nili, N., Strauss, B.H., and Farwell, S.M. 2002. Doxycycline modulates smooth muscle cell growth, migration, and matrix remodeling after arterial injury. Am. J. Pathol. 160: 1089-1095.
4. Berk, B.C. 2001. Vascular smooth muscle growth: autocrine growth mechanisms. Physiol. Rev. 81: 999-1030.
5. Cai, H., Griendling, K.K., and Harrison, D.G. 2003. The vascular NAD(P)H oxidases as therapeutic targets in cardiovascular diseases. Trends Pharmacol. Sci. 24: 471-478. doi:10.1016/S0165-6147(03)00233-5.
6. Carpenter, G. 2000. EGF receptor transactivation mediated by the proteolytic production of EGF-like agonists. Sci. STKE, 2000: PE1.
7. Chen, K., Vita, J.A., Berk, B.C., and Keaney, J.F., Jr. 2001. c-Jun N-terminal kinase activation by hydrogen peroxide in endothelial cells involves SRC-dependent epidermal growth factor receptor transactivation. J. Biol. Chem. 276: 16045-16050. doi:10.1074/jbc.M011766200.
8. Cockett, M.I., Murphy, G., Birch, M.L., O'Connell, LP., Crabbe, T., Millican, A.T., Hart, I.R., and Docherty, A.J. 1998. Matrix metalloproteinases and metastatic cancer. Biochem. Soc. Symp. 63: 295-313.
9. Courtman, D.W., Franco, C.D., Meng, Q., and Bendeck, M.P. 2004. Inward remodeling of the rabbit aorta is blocked by the matrix metalloproteinase inhibitor doxycycline. J. Vasc. Res. 41: 157-165. doi:10.1159/000077145.
10. Cowan, K.N., Jones, P.L., and Rabinovitch, M. 2000. Elastase and matrix metalloproteinase inhibitors induce regression, and tenascin-C antisense prevents progression, of vascular disease. J. Clin. Invest. 105: 21-34.
11. Darmoul, D., Gratio, V., Devaud, H., Peiretti, F., and Laburth, M. 2004. Activation of proteinase-activated receptor 1 promotes human colon cancer cell proliferation through epidermal growth factor receptor transactivation. Mol. Cancer Res. 2: 514-522.
12. de Champlain, J., Wu, R., Girouard, H., Karas, M., El Midaoui, A., Laplante, M.A., and Wu, L. 2004. Oxidative stress in hypertension. Clin. Exp. Hypertens. 26: 593-601. doi:10.1081/CEH-200031904.
13. Fernandez-Patron, C., Martinez-Cuesta, M.A., Salas, E., Sawicki, G., Wozniak, M., Radomski, M.W., and Davidge, S.T. 1999a. Differential regulation of platelet aggregation by matrix metalloproteinases-9 and -2. Thromb. Haemost. 82: 1730-1735.
14. Fernandez-Patron, C., Zhang, Y., Radomski, M.W., Hollenberg, M.D., and Davidge, S.T. 1999b. Rapid release of matrix metalloproteinase (MMP)-2 by thrombin in the rat aorta: modulation by protein tyrosine kinase/phosphatase. Thromb. Haemost. 82: 1353-1357.
15. Finkel, T. 2000. Redox-dependent signal transduction. FEBS Lett. 476: 52-54. doi:10.1016/S0014-5793(00)01669-0.
16. Finkel, T. 2001. Reactive oxygen species and signal transduction. IUBMB Life, 52: 3-6.
17. Florian, J.A., and Watts, S.W. 1999. Epidermal growth factor: a potent vasoconstrictor in experimental hypertension. Am. J. Physiol. 276: H976-H983.
18. Fortuno, A., Jose, G.S., Moreno, M.U., Diez, J., and Zalba, G. 2005. Oxidative stress and vascular remodelling. Exp. Physiol. 90: 457-462. doi:10.1113/expphysiol.2005.030098.
19. Fujino, T., Hasebe, N., Fujita, M., Takeuchi, K., Kawabe, J., Tobise, K., et al. 1998. Enhanced expression of heparin-binding EGF-like growth factor and its receptor in hypertrophied left ventricle of spontaneously hypertensive rats. Cardiovasc. Res. 38: 365-374. doi:10.1016/S0008-6363(98)00010-8.
20. Galis, Z.S., Asanuma, K., Godin, D., and Meng, X. 1998. N-acetyl-cysteine decreases the matrix-degrading capacity of macrophage-derived foam cells: new target for antioxidant therapy? Circulation, 97: 2445-2453.
21. Griendling, K.K., Sorescu, D., and Ushio-Fukai, M. 2000. NAD(P)H oxidase: role in cardiovascular biology and disease. Circ. Res. 86: 494-501.
22. Hao, L., Du, M., Lopez-Campistrous, A., and Fernandez-Patron, C. 2004. Agonist-induced activation of matrix metalloproteinase-7 promotes vasoconstriction through the epidermal growth factor-receptor pathway. Circ. Res. 94: 68-76. doi:10.1161/01.RES.0000109413.57726.91.
23. Hao, L., Nishimura, T., Wo, H., and Fernandez-Patron, C. 2006. Vascular responses to alpha 1-adrenergic receptors in small rat mesenteric arteries depend on mitochondrial reactive oxygen species. Arterioscler. Thromb. Vasc. Biol. 26: 819-825.
24. Haro, H., Crawford, H.C., Fingleton, B., Shinomiya, K., Spengler, D.M., and Matrisian, L.M. 2000. Matrix metalloproteinase-7-dependent release of tumor necrosis factor-alpha in a model of herniated disc resorption. J. Clin. Invest. 105: 143-150.
25. Harrison, D.C. 1987. Pharmacokinetic and pharmacodynamic properties of beta-blocking drugs influencing choice in treatment of systemic hypertension. Am. J. Cardiol. 60: 13E-16E. doi:10.1016/0002-9149(87)90536-4.
26. Kagiyama, S., Eguichi, S., Frank, G.D., Inagami, T., Zhang, Y.C., and Phillips, M.I. 2002. Angiotensin II-induced cardiac hypertrophy and hypertension are attenuated by epidermal growth factor receptor antisense. Circulation, 106: 909-912. doi:10.1161/01.CIR.0000030181.63741.56.
27. Kagiyama, S., Qian, K., Kagiyama, T., and Phillips, M.I. 2003. Antisense to epidermal growth factor receptor prevents the development of left ventricular hypertrophy. Hypertension, 41: 824-829. doi:10.1161/01.HYP.0000047104. 42047.9B.
28. Kalmes, A., Daum, G., and Clowes, A.W. 2001. EGFR transactivation in the regulation of SMC function. Ann. N.Y. Acad. Sci. 947: 42-54.
29. Kimura, S., Zhang, G.X., Nishiyama, A., Shokoji, T., Yao, L., Fan, Y.Y., Rahman, M., and Abe, Y. 2005. Mitochondria-derived reactive oxygen species and vascular MAP kinases: comparison of angiotensin II and diazoxide. Hypertension, 45: 438-444. doi:10.1161/01.HYP.0000157169.27818.ae.
30. Koh, K.K., Ahn, J.Y., Han, S.H., Kim, D.S., Jin, D.K., Kim, H.S., et al. 2003. Pleiotropic effects of angiotensin II receptor blocker in hypertensive patients. J. Am. Coll. Cardiol. 42: 905-910. doi:10.1016/S0735-1097(03) 00846-5.
31. Lautrette, A., Li, S., Alili, R., Sunnarborg, S.W., Burtin, M., Lee, D.C., Friedlander, G., and Terzi, F. 2005. Angiotensin II and EGF receptor cross-talk in chronic kidney diseases: a new therapeutic approach. Nat. Med. 11: 867-874. doi:10.1038/nm1275.
32. Liebmann, C. 2001. Regulation of MAP kinase activity by peptide receptor signaling pathway: paradigms of multiplicity. Cell. Signal. 13: 777-785. doi:10.1016/S0898-6568(01)00192-9.
33. Lifton, R.P., Gharavi, A.G., and Geller, D.S. 2001. Molecular mechanisms of human hypertension. Cell, 104: 545-556. doi:10.1016/S0092-8674(01) 00241-0.
34. Liu, X.Q., and Pawson, T. 1991. The epidermal growth factor receptor phosphorylates GTPase-activating protein (GAP) at Tyr-460, adjacent to the GAP SH2 domains. Mol. Cell. Biol. 11: 2511-2516.
35. Morgan, K.G. 1987. Calcium and vascular smooth muscle tone. Am. J. Med. 82: 9-15. doi:10.1016/0002-9343(87)90205-1.
36. Mulvany, M.J. 1987. Vascular structure and smooth muscle contractility in experimental hypertension. J. Cardiovasc. Pharmacol. 10: Suppl. 6, S79-S85.
37. Overall, C.M. 2004. Dilating the degradome: matrix metalloproteinase 2 (MMP-2) cuts to the heart of the matter. Biochem. J. 383: e5-e7.
38. Pai, R., Soreghan, B., Szabo, I.L., Pavelka, M., Baatar, D., and Tarnawski, A.S. 2002. Prostaglandin E2 transactivates EGF receptor: a novel mechanism for promoting colon cancer growth and gastrointestinal hypertrophy. Nat. Med. 8: 289-293. doi:10.1038/nm0302-289.
39. Prenzel, N., Zwick, E., Daub, H., Leserer, M., Abraham, R., Wallasch, C., and Ullrich, A. 1999. EGF receptor transactivation by G-protein-coupled receptors requires metalloproteinase cleavage of proHB-EGF. Nature (London), 402: 884-888.
40. Purdom, S., and Chen, Q.M. 2005. Epidermal growth factor receptor-dependent and -independent pathways in hydrogen peroxide-induced mitogen-activated protein kinase activation in cardiomyocytes and heart fibroblasts. J. Pharmacol. Exp. Ther. 312: 1179-1186.
41. Rozakis-Adcock, M., Fernley, R., Wade, J., Pawson, T., and Bowtell, D. 1993. The SH2 and SH3 domains of mammalian Grb2 couple the EGF receptor to the Ras activator mSosl. Nature (London), 363: 83-85. doi:10.1038/363083a0.
42. Shah, B.H., and Catt, K.J. 2004. Matrix metalloproteinase-dependent EGF receptor activation in hypertension and left ventricular hypertrophy. Trends Endocrinol. Metab. 15: 241-243.
43. Shiuchi, T., Iwai, M., Li, H.S., Wu, L., Min, L.J., Li, J.M., et al. 2004. Angiotensin II type-1 receptor blocker valsartan enhances insulin sensitivity in skeletal muscles of diabetic mice. Hypertension, 43: 1003-1010. doi:10.1161/01.HYP.0000125142.41703.64.
44. Sorescu, D., Weiss, D., Lassegue, B., Clempus, R.E., Szocks, K., Sorescu, G.P., et al. 2002. Superoxide production and expression of nox family proteins in human atherosclerosis. Circulation, 105: 1429-1435. doi:10.1161/01.CIR.0000012917.74432.66.
45. Swaminathan, N., Vincent, M., Sassard, J., and Sambhi, M.P. 1996. Elevated epidermal growth factor receptor levels in hypertensive Lyon rat kidney and aorta. Clin. Exp. Pharmacol. Physiol. 23: 793-796.
46. Tanaka, M., Nanba, D., Mori, S., Shiba, F., Ishiguro, H., Yoshino, K., Matsuura, N., and Higashiyama, S. 2004. ADAM binding protein Eve-1 is required for ectodomain shedding of epidermal growth factor receptor ligands. J. Biol. Chem. 279: 41950-41959. doi:10.1074/jbc.M400086200.
47. Touyz, R.M. 2003. Recent advances in intracellular signalling in hypertension. Curr. Opin. Nephrol. Hypertens. 12: 165-174. doi:10.1097/00041552-200303000-00007.
48. Touyz, R.M. 2005a. Intracellular mechanisms involved in vascular remodelling of resistance arteries in hypertension: role of angiotensin II. Exp. Physiol. 90: 449-455. doi:10.1113/expphysiol.2005.030080.
49. Touyz, R.M. 2005b. Molecular and cellular mechanisms in vascular injury in hypertension: role of angiotensin II. Curr. Opin. Nephrol. Hypertens. 14: 125-131.
50. Touyz, R.M. 2006. Mitochondrial redox control of matrix metalloproteinase signaling in resistance arteries. Arterioscler. Thromb. Vasc. Biol. 26: 685-688.
51. Ulanet, D.B., Flavahan, N.A., Casciola-Rosen, L., and Rosen, A. 2004. Selective cleavage of nucleolar autoantigen B23 by granzyme B in differentiated vascular smooth muscle cells: insights into the association of specific autoantibodies with distinct disease phenotypes. Arthritis Rheum. 50: 233-241. doi:10.1002/art.11485.
52. Vaziri, N.D. 2004. Oxidative stress in uremia: nature, mechanisms, and potential consequences. Semin. Nephrol. 24: 469-473.
53. Verhaar, M.C., Honing, M.L., van Dam, T., Zwart, M., Koomans, H.A., Kastelein, J.J., and Rabelink, T.J. 1999. Nifedipine improves endothelial function in hypercholesterolemia, independently of an effect on blood pressure or plasma lipids. Cardiovasc. Res. 42: 752-760. doi:10.1016/S0008- 6363(98) 00341-1.
54. Waypa, G.B., and Schumacker, P.T. 2005. Hypoxic pulmonary vasoconstriction: redox events in oxygen sensing. J. Appl. Physiol. 98: 404-414.
55. Wilson, E.M., and Spinale, F.G. 2001. Myocardial remodelling and matrix metalloproteinases in heart failure: turmoil within the interstitium. Ann. Med. 33: 623-634.
56. Yan, Y., Shirakabe, K., and Werb, Z. 2002. The metalloprotease Kuzbanian (ADAM10) mediates the transactivation of EGF receptor by G protein-coupled receptors. J. Cell Biol. 158: 221-226. doi:10.1083/jcb.200112026.
57. Zhang, H., Chalothorn, D., Jackson, L.F., Lee, D.C., and Faber, J.E. 2004. Transactivation of epidermal growth factor receptor mediates catecholamine-induced growth of vascular smooth muscle. Circ. Res. 95: 989-997. doi:10.1161/01.RES.0000147962.01036.bb.
58. Zhou, M.S., Jaimes, E.A., and Raij, L. 2004. Atorvastatin prevents end-organ injury in salt-sensitive hypertension: role of eNOS and oxidant stress. Hypertension, 44: 186-190. doi:10.1161/01.HYP.0000136395.06810. cf.
59. Zwick, E., Hackel, P.O., Prenzel, N., and Ullrich, A. 1999. The EGF receptor as central transducer of heterologous signalling systems. Trends Pharmacol. Sci. 20: 408-412. doi:10.1016/S0165-6147(99)01373-5.